157 related articles for article (PubMed ID: 22875412)
21. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure.
Bayes-Genis A; Pascual-Figal D; Fabregat J; Domingo M; Planas F; Casas T; Ordoñez-Llanos J; Valdes M; Cinca J
Int J Cardiol; 2007 Sep; 120(3):338-43. PubMed ID: 17174423
[TBL] [Abstract][Full Text] [Related]
22. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.
Bettencourt P; Azevedo A; Pimenta J; Friões F; Ferreira S; Ferreira A
Circulation; 2004 Oct; 110(15):2168-74. PubMed ID: 15451800
[TBL] [Abstract][Full Text] [Related]
23. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial.
Huelsmann M; Neuhold S; Resl M; Strunk G; Brath H; Francesconi C; Adlbrecht C; Prager R; Luger A; Pacher R; Clodi M
J Am Coll Cardiol; 2013 Oct; 62(15):1365-72. PubMed ID: 23810874
[TBL] [Abstract][Full Text] [Related]
24. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
Bhardwaj A; Rehman SU; Mohammed AA; Gaggin HK; Barajas L; Barajas J; Moore SA; Sullivan D; Januzzi JL
Am Heart J; 2012 Nov; 164(5):793-799.e1. PubMed ID: 23137512
[TBL] [Abstract][Full Text] [Related]
25. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score.
Salah K; Kok WE; Eurlings LW; Bettencourt P; Pimenta JM; Metra M; Bayes-Genis A; Verdiani V; Bettari L; Lazzarini V; Damman P; Tijssen JG; Pinto YM
Heart; 2014 Jan; 100(2):115-25. PubMed ID: 24179162
[TBL] [Abstract][Full Text] [Related]
26. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
27. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure.
Corell P; Gustafsson F; Kistorp C; Madsen LH; Schou M; Hildebrandt P
Int J Cardiol; 2007 May; 117(3):395-402. PubMed ID: 16919342
[TBL] [Abstract][Full Text] [Related]
28. Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure.
Velibey Y; Golcuk Y; Golcuk B; Oray D; Atilla OD; Colak A; Kurtulmus Y; Erbay AR; Yilmaz A; Eren M
Am J Emerg Med; 2013 Dec; 31(12):1634-7. PubMed ID: 24055249
[TBL] [Abstract][Full Text] [Related]
29. The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure.
Schou M; Gustafsson F; Corell P; Kistorp CN; Kjaer A; Hildebrandt PR
Am Heart J; 2007 Jul; 154(1):123-9. PubMed ID: 17584564
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
Hartmann F; Packer M; Coats AJ; Fowler MB; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Anker SD; Amann-Zalan I; Hoersch S; Katus HA
Circulation; 2004 Sep; 110(13):1780-6. PubMed ID: 15381643
[TBL] [Abstract][Full Text] [Related]
31. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients.
Schou M; Gustafsson F; Kjaer A; Hildebrandt PR
Eur Heart J; 2007 Jan; 28(2):177-82. PubMed ID: 17218450
[TBL] [Abstract][Full Text] [Related]
32. Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.
Sanders-van Wijk S; Muzzarelli S; Neuhaus M; Kiencke S; Maeder M; Estlinbaum W; Tobler D; Mayer K; Erne P; Pfisterer ME; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Aug; 15(8):910-8. PubMed ID: 23666681
[TBL] [Abstract][Full Text] [Related]
33. N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome.
Rutten JH; Steyerberg EW; Boomsma F; van Saase JL; Deckers JW; Hoogsteden HC; Lindemans J; van den Meiracker AH
Am Heart J; 2008 Jul; 156(1):71-7. PubMed ID: 18585499
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic value of N-terminal-pro-brain natriuretic peptide on admission in patients with chronic heart failure].
Wang F; Li W; Huang J; Wang L; Bian WY; Pang HM; Wang Y; Xu ZM; Li YS
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Jan; 34(1):28-32. PubMed ID: 16626545
[TBL] [Abstract][Full Text] [Related]
35. Impact of triiodothyronine and N-terminal pro-B-type natriuretic peptide on the long-term survival of critically ill patients with acute heart failure.
Chuang CP; Jong YS; Wu CY; Lo HM
Am J Cardiol; 2014 Mar; 113(5):845-50. PubMed ID: 24406111
[TBL] [Abstract][Full Text] [Related]
36. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.
Khan SQ; Ng K; Dhillon O; Kelly D; Quinn P; Squire IB; Davies JE; Ng LL
Eur Heart J; 2009 May; 30(9):1057-65. PubMed ID: 19168526
[TBL] [Abstract][Full Text] [Related]
37. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.
Berger R; Moertl D; Peter S; Ahmadi R; Huelsmann M; Yamuti S; Wagner B; Pacher R
J Am Coll Cardiol; 2010 Feb; 55(7):645-53. PubMed ID: 20170790
[TBL] [Abstract][Full Text] [Related]
38. Effect of atrioventricular optimization on circulating N-terminal pro brain natriuretic peptide following cardiac resynchronization therapy.
Shanmugam N; Campos AG; Prada-Delgado O; Bizrah M; Valencia O; Jones S; Collinson P; Anderson L
Eur J Heart Fail; 2013 May; 15(5):534-42. PubMed ID: 23388091
[TBL] [Abstract][Full Text] [Related]
39. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
[TBL] [Abstract][Full Text] [Related]
40. Are there long-term benefits in following stable heart failure patients in a heart failure clinic?
Leetmaa TH; Villadsen H; Mikkelsen KV; Davidsen F; Haghfelt T; Videbaek L
Scand Cardiovasc J; 2009 Jun; 43(3):158-62. PubMed ID: 19065446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
